Virus Detection

Microfluidics Technology in Viral Detection and Infectious Disease Research

Microfluidics Technology in Infectious Disease Research and Surveillance

In a short period of time, a novel coronavirus (SARS-CoV-2) has impacted our lives, society and health care infrastructure. To address critical needs for clinical research and public health surveillance, Fluidigm products are supporting global laboratory efforts by delivering:

  • Cost-efficient workflows that minimize reagent consumption using microfluidics technology

  • Scalable throughput that enables the testing of >6,000 samples per day

  • Flexible panel designs that enable users to easily add, remove or change assays without changing technologies

Labs around the world have leveraged the benefits of Fluidigm microfluidics for research and implemented high-throughput lab developed tests (LDT) for SARS-CoV-2 detection.

Whether you are seeking to gain new insights into infectious disease research or public health surveillance or to accelerate therapeutic development, we can help you reach your goal.

Get more information about viral detection with Fluidigm.


Joel Guthridge, PhD
Assistant Member, Arthritis and Clinical Immunology Research Program
Director of Translational Informatics & Clinical Resources
Director of Human Phenotyping Core and of Biorepository 
Oklahoma Medical Research Foundation




Publications and Resources
Available now: Pathogen Detection Using the Advanta RT-PCR Kit

Infectious disease research and surveillance play a critical role in improving global health care. Information acquired from research drives public health policy for preventive measures, drug treatment and vaccine development. PCR based applications such as reverse transcription polymerase chain reaction (RT-PCR) are commonly used to detect viral and bacterial pathogens.

The Advanta RT-PCR Kit—192.24 provides scalable, high-throughput pathogen detection through nanoliter-scale volumes with walkaway automation. Using the 192.24 Dynamic Array™ IFC (integrated fluidic circuit) enables rapid data acquisition of up to 192 samples across 24 targets: up to 4,608 reactions every 35 minutes.

For Research Use Only. Not for use in diagnostic procedures.

Features Benefits
Proprietary microfluidics technology Nanoliter-volume reactions ensure low cost per sample.
Modular system that allows up to 6,000 samples to be processed in a day Highly scalable to fit laboratory’s needs
Up to 24 molecular targets in a single run Preserve precious sample while providing comprehensive molecular pictures of the sample.
Up to 4,608 datapoints in a single run Save time by accessing more information per run.
Advanta RT-PCR Kit—192.24, 10 IFCs

This kit enables probe-based qPCR of 1,920 samples and combines reverse transcription and preamplification in a single step.
Scalable High-Throughput Viral RNA Detection

Efficient—Maximize your budget with microfluidics technology by using up to 50 times less reagent than traditional PCR methods.

Scalable—Run nearly 6,000 samples in a 24-hour workflow on each Biomark HD and Juno™ system.

Flexible—Detect up to 24 unique pathogens per sample, such as SARS-CoV-2, influenza A and other respiratory disease pathogens.

Learn more about the assay from the quick reference (QR) guide, which describes in detail:
  • The workflow
  • Materials including Fluidigm and third-party reagents and kits
  • Consumables and equipment
  • Detailed procedures for viral RNA detection

Learn more about Biomark HD

Get more information
For Research Use Only. Not for use in diagnostic procedures.